Immunotherapy

You have access
Microsatellite Instability-high Signet Ring Cell Carcinoma of the Colon Treated With Immunotherapy: Report of a Case
KOTA ARIMA, NORIO UEMURA, KENGO TSUNEYOSHI, HIROSHI FUJITA, HIDEYUKI KUROKI, SHINICHIRO UEMURA, NORIHISA HANADA, HIDEO BABA and YOSHIHIRO KOMOHARA

Anticancer Research October 2023, 43 (10) 4729-4733; DOI: https://doi.org/10.21873/anticanres.16669
Open Access
New Approaches Towards Targeted Therapy for Childhood Neuroblastoma
TINA DALIANIS, MONIKA LUKOSEVICIUTE, STEFAN HOLZHAUSER and OURANIA N. KOSTOPOULOU

Anticancer Research September 2023, 43 (9) 3829-3839; DOI: https://doi.org/10.21873/anticanres.16570
You have access
Determination of Cuproptosis-related Subtypes, Development of a Prognostic Model, and Characterization of Tumor Microenvironment Infiltration in Acute Myeloid Leukemia
YUCHEN TAO, JIANYE REN, TINGTING XUE, YANLU WANG, HAO XU, HONGYU ZHANG and JIAHUI LU

Anticancer Research September 2023, 43 (9) 3943-3960; DOI: https://doi.org/10.21873/anticanres.16582
You have access
Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy
MASAFUMI IGUCHI, SHIGEKI YAGYU, KOSUKE KAMBE, MAYUMI HIGASHI, SHIGEHISA FUMINO, TSUNAO KISHIDA, TOMOKO IEHARA, OSAM MAZDA and TATSURO TAJIRI

Anticancer Research June 2023, 43 (6) 2417-2424; DOI: https://doi.org/10.21873/anticanres.16409
You have access
Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes
EVA PROBST, KLAAS F. FRANZEN, CHRISTIAN IDEL, KIRSTIN PLÖTZE-MARTIN, JONAS FLECKNER, DIRK RADES, SABINE BOHNET, KARL-LUDWIG BRUCHHAGE and RALPH PRIES

Anticancer Research June 2023, 43 (6) 2445-2454; DOI: https://doi.org/10.21873/anticanres.16412
You have access
Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
HYERA KIM, DONG HYUN LIM, YONG SHIK KWON, MI AE KIM and KEON UK PARK

Anticancer Research May 2023, 43 (5) 2343-2349; DOI: https://doi.org/10.21873/anticanres.16399
Open Access
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
ERLINDA M. GORDON, NICOLE L. ANGEL, NADEZHDA OMELCHENKO, VICTORIA S. CHUA-ALCALA, ANIA MORADKHANI, DORIS QUON and STEVEN WONG

Anticancer Research May 2023, 43 (5) 1993-2002; DOI: https://doi.org/10.21873/anticanres.16360
You have access
Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data
KENJI NAKAHAMA, MOTOHIRO IZUMI, NAOKI YOSHIMOTO, MITSURU FUKUI, AKIRA SUGIMOTO, HIROAKI NAGAMINE, KOICHI OGAWA, KENJI SAWA, YOKO TANI, HIROYASU KANEDA, SHIGEKI MITSUOKA, TETSUYA WATANABE, KAZUHISA ASAI and TOMOYA KAWAGUCHI

Anticancer Research May 2023, 43 (5) 2185-2197; DOI: https://doi.org/10.21873/anticanres.16381
You have access
Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
LOLA MACIA-RIVAS, CLARA LUZ FERNANDEZ-LAGUNA, CRISTINA ALVAREZ-ASTEINZA, IVAN MARAY, MONICA CARBAJALES-ALVAREZ and ANA LOZANO-BLAZQUEZ

Anticancer Research April 2023, 43 (4) 1681-1688; DOI: https://doi.org/10.21873/anticanres.16320
Open Access
Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
PASCALE ALICIA HOELL, KHALED ELSAYAD, HENDRIK BERSSENBRUEGGE, DOMINIK HERING, CHRISTOPHER KITTEL, JOHANNES KLEINHEINZ, ANNALEN BLECKMANN, GEORG EVERS, EVA WARDELMANN, CLAUDIA RUDACK and HANS THEODOR EICH

Anticancer Research March 2023, 43 (3) 1255-1263; DOI: https://doi.org/10.21873/anticanres.16272

Main menu

User menu

Search

Immunotherapy

Pages